Zealous Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 157.39%
- Profit Growth 254.34%
- Ebitda 314.53%
- Net Worth 53.50%
- Total Assets 111.30%
About Zealous Pharmaceuticals
Zealous Pharmaceuticals Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 May 2017 (Seven years and nine months 8 days old ). Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Umesh Pandey, Shakuntala Roy, and Prasanjeet Roy serve as directors at the Company.
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304MP2017PTC043360
- Company No.
043360
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2017
- Date of AGM
12 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Zealous Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasanjeet Roy  | Director | 19-May-2017 | Current |
| Umesh Pandey | Director | 07-Dec-2018 | Current |
| Shakuntala Roy | Director | 19-May-2017 | Current |
Financial Performance of Zealous Pharmaceuticals.
Zealous Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 157.39% increase. The company also saw a substantial improvement in profitability, with a 254.34% increase in profit. The company's net worth Soared by an impressive increase of 53.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zealous Pharmaceuticals?
Unlock access to Zealous Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zealous Pharmaceuticals?
Unlock and access historical data on people associated with Zealous Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zealous Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zealous Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.